ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
Retrieved on:
Wednesday, May 25, 2022
International Society, Catholic higher education, HMB, Gynecological Endocrinology, EDELWEISS, Uterine fibroid, Catholic University of Leuven (1834–1968), Doctor of Philosophy, World Congress, PRIMROSE, NASDAQ, LGX, Constipation, Gonadotropin-releasing hormone, Treatment, DYS, Uterus, MBL, Congress, Yale School of Medicine, Safety, Dysmenorrhea, ABT, Pharmaceutical industry, Birth control, Medical imaging, Endometriosis, Woman, MD
GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.
Key Points:
- GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.
- The encouraging data presented at these important medical congresses highlight the differentiated therapeutic potential of linzagolix to better address the individual needs of women with uterine fibroids and endometriosis, said Dr. Brandi Howard, Chief Clinical Officer of ObsEva.
- These data demonstrate that linzagolix with or without add-back therapy (ABT) significantly reduced heavy menstrual bleeding due to uterine fibroids.
- Linzagolix is an investigational novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3.